This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version    RSS    Subscribe    Unsubscribe    Archive    Media Kit Aug. 31, 2012

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us  


The rise of the cyborgs: Scientists reveal new method to 'grow' electronic sensors inside human tissue
Daily Mail    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Cyborgs melding human and robotic technology together have finally come a step closer to reality. Researchers at MIT in Boston have revealed a new technique that can place sensors inside human tissue. To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds.

Related articles:
First ever artificial 'cyborg' tissue developed (Press Trust of India via Business Standard)
'Cyborg' tissues take science of organ transplant to a whole new level (Asian News Internatinoal via

Roslyn Mannon, MD

Conversations with the President

In her latest blog post, AST President, Dr. Roslyn Mannon writes about formulating a Clinical Research Community of Practice. Read the blog.


Submit abstracts now for AST's Cutting Edge of Transplantation (CEOT) 2013 meeting
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Not a clinical meeting, not a research meeting — simply the cutting edge of both. "B Cells from Bedside to Bench to Bedside: A Comprehensive Look at B Cells and Antibodies in Transplantation," will be held Feb. 14-16, 2013 in Phoenix, at the Sheraton Wild Horse Pass.

AST's first Cutting Edge of Transplantation (CEOT) meeting is a multi-expert view of the most important clinical and research problems in transplantation. Integrated clinical transplant and basic science talks define best approaches to management and research questions.

Abstract submission is now open. Clinical, basic and translational abstracts related to the meeting topic will be considered. Submit as many as you'd like!

Join clinical and basic science experts to address key management and research questions: What is the state of the field and the challenges to successfully transplanting sensitized patients? How does the immunobiology of B cells, plasma cells and antibody inform these challenges to clinical practice and suggest solutions? What are the best desensitization protocols and alternative therapies and their short- and long-term outcomes? Where are we in 'precision diagnosis' and continued monitoring of antibody-mediated rejection (AMR)?

Valentine's Day with AST: CEOT is about the joy of discovery. On Valentine's Day 2013, share that joy and discover the wild beauty of the desert with your loved one. Let the spirit of this ancient land breathe new energy into your lives together in a spectacular setting.

C1qScreen™: A New Research Tool for AMR Risk
Identify Antibodies That May Compromise Graft Survival
  • Detect Presence of Complement Fixing Antibodies
  • Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!

For Research Use Only. Not for use in diagnostic procedures.

Poll: What is your preferred method for receiving your membership dues notice?
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
AST would like your feedback. We are considering offering members a paperless option for membership dues renewal notices. Please take our poll here.

New addition to the Timely Topics in Transplantation Webcast Series
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Use your AST user login information to watch a free 30-minute webcast summarizing the Kidney Paired Donation (KPD) Consensus Conference held in March of this year. Click here and log in on the left hand side of the page (disregard the $25 price displayed on the right hand side of the page, this is for non-members). This webcast is part of the Timely Topics in Transplantation 2012 Webcast Series and will soon be posted on the AST website. View past free webcasts at

The primary objective of this consensus conference was to identify and recommend best practices related to living kidney donor education and evaluation processes, communication processes, attenuation of participation barriers and donor follow-up care in the multi-center KPD setting. You will learn about alternative KPD allocation systems currently in use, challenges unique to KPD in terms of donor evaluation, geography, financing, histocompatibility and implementation and future directions for KPD allocation.

Athena Diagnostics

Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.

The ESOT-AST Joint Meeting: Cutting edge science
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
"Transformational Therapies and Diagnostics in Transplantation," will be held on Oct. 12-14 at Palais de la Méditerranée in Nice, France. ESOT and AST have partnered once again to present the best transplantation science. The international faculty will critically analyze important topics such as: The results of recent clinical trials using costimulation blockade, new challenges in the diagnosis and treatment of antibody mediated rejection, pharmacogenetic testing in patient management, new immunosuppressive agents in the pipeline, new interventions for delayed graft function and graft fibrosis and current immunosuppressive therapies and identify unfulfilled needs and potential new interventions.

Register by Sept. 21 to take advantage of the early registration discounted rates. Register online at View the program and travel information here.


Autistic man denied heart transplant
The Daily Pennsylvanian    Share    Share on FacebookTwitterShare on LinkedinE-mail article
After an autistic patient was denied a heart transplant at the Hospital of the University of Pennsylvania, his mother started a petition to reverse the decision and place her son on the transplant list. Paul Corby, Karen Corby's 23-year-old son, was diagnosed in 2008 with left ventricular noncompaction, a congenital disorder that impairs the left part of his heart which pumps blood through his body. In 2011, Paul was referred to Penn Medicine, but was denied a heart transplant due to "psychiatric issues, autism, the complexity of the process, multiple procedures and the unknown and unpredictable effect of steroids on behavior," according to a June 2011 letter from his cardiologist at the time.

Related articles:
Penn Medicine breaks silence on transplants for people with autism (Babble)
Autism transplant denial sparks debate (ABC News)

Optimal treatment for most common infection after organ transplantation
Medical News Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Waiting to treat the most common viral infections in transplant recipients until they reach a certain threshold is better than prophylactically treating all recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. Cytomegalovirus infection is the most common infection in organ transplant recipients, who are susceptible to infections in general because they must take immunosuppressive medications long term.

Related article:
Study reveals optimal treatment for most common infection after organ transplantation (Science Codex)

Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
By analyzing 26,414 patients [12,589 with hepatitis C virus (HCV)] in the Scientific Registry of Transplant Recipients database, researchers sought to determine comparative risk factors (including primary immunosuppression) predictive of death and graft loss among patients with HCV and patients without HCV. This study suggests a novel association between sirolimus use and an increased risk of death and graft loss after liver transplantation in HCV patients that is not seen in patients without HCV. More

ESC: Copeptin level in CHF may predict death
MedPage Today (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
High levels of the biomarker copeptin appear to predict an increased mortality risk for heart failure patients, researchers said.

Related article:
Copeptin estimates prognosis in patients with heart failure (News Medical)

Clinical factors predicting readmission after orthotopic liver transplantation
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Hospitals with the highest readmission rates for high-cost conditions may be targeted for payment penalties. The primary aim of this study was to determine clinical predictors of 30-day readmission after discharge for patients undergoing orthotopic liver transplantation at the University of Washington from January 2003 to October 2010. More

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Aug. 23, 2012
Aug. 16, 2012
Aug. 9, 2012
Aug. 2, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063